| Name: | R-Tech Ueno, Ltd. |
| Established: | September 1989 |
| HEAD OFFICE: | NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho, Chiyoda-ku, Tokyo 100-0011, Japan Tel: +81-3-3596-8011 Fax: +81-3-3596-8023  |
| KOBE R&D Institute: | Kobe Hybrid Business Center, 3F, 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City, Hyogo 650-0047, Japan Tel: +81-78-599-5340 Fax: +81-78-599-5352 |
| SANDA OFFICE: （Laboratories and Plants） |
4-1 Techno-Park, Sanda, Hyogo 669-1339, Japan Tel: +81-79-560-7181 Fax: +81-79-560-7180 |
| Capital: | 653,987,000 yen |
| Number of Employees: | 78 (As of March 31, 2011) |
| Representative: | Yukihiko Mashima (President) |
| Business: | Research and development, manufacture, sales, Development Assistance and Contract Manufacturing Services of pharmaceutical products |
| Board Director: | Yukihiko Mashima (President) Tadashi Hayashi (Managing Director) Shinya Homma |
| Corporate Auditor: | Kenji Seo Eiji Asada Kazuyuki Taguchi |
| Audit Corporation: | Deloitte Touche Tohmatsu LLC. |
September, 1989 |
Established for manufacturing, marketing and R & D of pharmaceuticals as major business objectives. |
April, 2001 |
Marketing and manufacturing operations for Rescula® Eye Drops was inherited from Ueno Fine Chemicals Industry，Ltd． |
April, 2003 |
Employees were transferred from Prescription Drug Division, Ueno Fine Chemicals Industry，Ltd． |
June, 2003 |
Pharma Chemical Division and Prescription Drug Division were established. |
September 2004 |
Headquarters moved to Chiyoda-ku, Tokyo |
October, 2004 |
Marketing affiliation for Rescula® Eye Drops was changed from Fujisawa Pharmaceutical Co., Ltd (actual Astellas Pharma Inc.) to Santen Pharmaceutical Co., Ltd. Contract for manufacturing and provision of Amitiza® capsule was made with Takeda Pharmaceutical Company Limited and Sucampo Pharmaceuticals, Inc. |
April, 2005 |
Translational Research Promotion Division was established. |
September, 2005 |
Sanda Office obtained approval for a factory manufacturing Amitiza® drug substance from U.S. Food and Drug Administration (FDA). |
September, 2006 |
Science group was established in Pharmaceutical Division for reinforcing domestic marketing of Rescula ® Eye Drops. |
April, 2008 |
Listed on Hercules, Osaka Securities Exchange. |
October, 2008 |
Sanda office obtained approval for a factory manufacturing Amitiza® drug substance from Medicines and Healthcare Products Regulatory Agency (MHRA), UK. |
February, 2009 |
Contract for exclusive manufacturing and provision of Amitiza® capsule to Japan, Asia and Oceania Areas was made. |
April, 2009 |
Contract for assignment of marketing approval and dealership of Rescula® Eye Drops, licensing of related patents, and exclusive manufacturing and provision of the product in U.S. and Canada for indications of glaucoma and ocular hypertension was made with Sucampo Pharma Americas, Inc. |
August, 2009 |
Ophthalmology and Dermatology Division and Medical Advisory Board were established. |
May, 2010 |
Sanda Office obtained approval for a factory manufacturing Rescula® Eye Drops from U.S. Food and Drug Administration (FDA). |
April, 2011 |
KOBE R&D Institute was established in Kobe City, Hyogo. |
